One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

AZ and Merck's drug is already approved by the FDA as a second-line treatment for BRCA-mutated, HER2-negative breast cancer, but approval of adjuvant use could unlock a significant new market for ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

Adjuvant ado-trastuzumab emtansine improved ... “Prior to [the KATHERINE trial], HER2-directed drug treatments for early breast cancer were administered either before or after surgery since ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.